https://opexatherapeutics.com/https://opexatherapeutics.com/011513_page_release_section_news_article_011513.htmlhttps://opexatherapeutics.com/012313_page_release_section_news_article_012313.htmlhttps://opexatherapeutics.com/020513_page_release_section_news_article_020513.htmlhttps://opexatherapeutics.com/020713_2.htmlhttps://opexatherapeutics.com/020713_2_page_release_section_news_article_020713_2.htmlhttps://opexatherapeutics.com/020713_page_release_section_news_article_020713.htmlhttps://opexatherapeutics.com/121412.htmlhttps://opexatherapeutics.com/121412_page_release_section_news_article_121412.htmlhttps://opexatherapeutics.com/?a.offsetWidth%3Aa.offsetHeight%3Bf%21=%3Dhttps://opexatherapeutics.com/?article=010511&page=release&section=newshttps://opexatherapeutics.com/?article=011712&page=release&section=newshttps://opexatherapeutics.com/?article=022712&page=release&section=newshttps://opexatherapeutics.com/?article=022912&page=release&section=newshttps://opexatherapeutics.com/?article=041410&page=release&section=newshttps://opexatherapeutics.com/?article=041912&page=release&section=newshttps://opexatherapeutics.com/?article=042710&page=release&section=newshttps://opexatherapeutics.com/?article=051110&page=release&section=newshttps://opexatherapeutics.com/?article=051112&page=release&section=newshttps://opexatherapeutics.com/?article=052112&page=release&section=newshttps://opexatherapeutics.com/?article=060710&page=release&section=newshttps://opexatherapeutics.com/?article=062811&page=release&section=newshttps://opexatherapeutics.com/?article=072612&page=release&section=newshttps://opexatherapeutics.com/?article=080510&page=release&section=newshttps://opexatherapeutics.com/?article=081312&page=release&section=newshttps://opexatherapeutics.com/?article=091012&page=release&section=newshttps://opexatherapeutics.com/?article=091211&page=release&section=newshttps://opexatherapeutics.com/?article=091212&page=release&section=newshttps://opexatherapeutics.com/?article=091712&page=release&section=newshttps://opexatherapeutics.com/?article=091911&page=release&section=newshttps://opexatherapeutics.com/?article=110411&page=release&section=newshttps://opexatherapeutics.com/?article=110811&page=release&section=newshttps://opexatherapeutics.com/?article=120911&page=release&section=newshttps://opexatherapeutics.com/?page=abilit&section=abilithttps://opexatherapeutics.com/?page=about&section=abouthttps://opexatherapeutics.com/?page=advisory-board&section=homehttps://opexatherapeutics.com/?page=board-of-directors&section=homehttps://opexatherapeutics.com/?page=calendar&section=newshttps://opexatherapeutics.com/?page=contact&section=abouthttps://opexatherapeutics.com/?page=contact&section=homehttps://opexatherapeutics.com/?page=home&section=homehttps://opexatherapeutics.com/?page=management&section=abouthttps://opexatherapeutics.com/?page=management&section=homehttps://opexatherapeutics.com/?page=overview&section=investorshttps://opexatherapeutics.com/?page=overview&section=patientshttps://opexatherapeutics.com/?page=positions&section=careershttps://opexatherapeutics.com/?page=privacy-policy%C2%A7ion%3Dhomehttps://opexatherapeutics.com/?page=privacy-policy&section=homehttps://opexatherapeutics.com/?page=releases&section=newshttps://opexatherapeutics.com/?page=sec&section=investorshttps://opexatherapeutics.com/?page=sitemap&section=homehttps://opexatherapeutics.com/?page=stock&section=homehttps://opexatherapeutics.com/?page=t-cell-platform&section=technologyhttps://opexatherapeutics.com/?page=terms-of-use&section=homehttps://opexatherapeutics.com/?page=tovaxinhttps://opexatherapeutics.com/?page=tovaxin&section=homehttps://opexatherapeutics.com/?page=tovaxin&section=partnershiphttps://opexatherapeutics.com/?page=tovaxin&section=tovaxinhttps://opexatherapeutics.com/?page=videoQA&section=abouthttps://opexatherapeutics.com/?page=webcasts&section=newshttps://opexatherapeutics.com/?page=working-at-opexa&section=careershttps://opexatherapeutics.com/CIK-0001069308/007a23af-fe99-4163-a61b-5cab77edc3db.htmlhttps://opexatherapeutics.com/CIK-0001069308/0d3e45b1-9a9b-4340-858c-bb18d39f7dfd.htmlhttps://opexatherapeutics.com/CIK-0001069308/17914145-66e2-44da-ad39-d9d47c183e2a.htmlhttps://opexatherapeutics.com/CIK-0001069308/28733ed4-e9df-47c0-a804-fbdbf68c1506.htmlhttps://opexatherapeutics.com/CIK-0001069308/2a06ddd4-a2f1-40bc-b6d4-ef6c89059d4a.htmlhttps://opexatherapeutics.com/CIK-0001069308/2b837a51-01c4-45ca-93f4-97cf04b4a412.htmlhttps://opexatherapeutics.com/CIK-0001069308/32881dd3-28f3-4276-a8bf-4958b9032f7e.htmlhttps://opexatherapeutics.com/CIK-0001069308/39de7130-c474-44b9-a35e-aa2b3ffa2cd2.htmlhttps://opexatherapeutics.com/CIK-0001069308/43fe175e-480d-4e12-81aa-1a425e0c953e.htmlhttps://opexatherapeutics.com/CIK-0001069308/48dabd6c-79ee-4408-aa29-2756fddaf8db.htmlhttps://opexatherapeutics.com/CIK-0001069308/57d009ba-46bf-49c6-9090-4775aca40902.htmlhttps://opexatherapeutics.com/CIK-0001069308/63a6969c-2188-4a99-9fa8-92d175ec34b5.htmlhttps://opexatherapeutics.com/CIK-0001069308/704662b8-b061-4d3f-b222-f80fbd44ed00.htmlhttps://opexatherapeutics.com/CIK-0001069308/748dfb01-039d-4e91-847c-a5c1c66f0724.htmlhttps://opexatherapeutics.com/CIK-0001069308/835def46-41fb-4997-b431-1ed879aa7bb1.htmlhttps://opexatherapeutics.com/CIK-0001069308/901cebaf-40a1-47f3-83d5-171b2e30d21b.htmlhttps://opexatherapeutics.com/CIK-0001069308/95d5061d-0100-4f25-901e-74af79c0ab75.htmlhttps://opexatherapeutics.com/CIK-0001069308/a8229777-9e3b-48cc-9dd1-750ef2f51c99.htmlhttps://opexatherapeutics.com/CIK-0001069308/a909f5dc-e706-41f8-b8ac-4065ff2a8166.htmlhttps://opexatherapeutics.com/CIK-0001069308/abac4e31-ce56-482e-89e6-5b2f23389ebf.htmlhttps://opexatherapeutics.com/CIK-0001069308/bc3148a3-060c-4db8-b998-467d6e84b2b0.htmlhttps://opexatherapeutics.com/CIK-0001069308/c4180477-8269-47d5-adcc-f34660e775a4.htmlhttps://opexatherapeutics.com/CIK-0001069308/cab10814-935a-4a4e-8bfa-41d210d22190.htmlhttps://opexatherapeutics.com/CIK-0001069308/d318d931-55f2-4710-a2f6-87b7e1aa1cae.htmlhttps://opexatherapeutics.com/CIK-0001069308/de18e578-0252-4b97-b790-2e9019d046e2.htmlhttps://opexatherapeutics.com/CIK-0001069308/f32c15f7-a014-4c96-b778-3fca60bb302c.htmlhttps://opexatherapeutics.com/CIK-0001069308/f96d3865-718c-4663-b179-c6d61c740395.htmlhttps://opexatherapeutics.com/CIK-0001069308/fded7d5e-c161-440c-81d8-afbd7d06bba9.htmlhttps://opexatherapeutics.com/English/investors-relations/email-alerts/default.htmlhttps://opexatherapeutics.com/Home/default_print_1.htmlhttps://opexatherapeutics.com/OPX-212/Neuromyelitis-Optica/default.htmlhttps://opexatherapeutics.com/OPX-212/Neuromyelitis-Optica/default_print_1.htmlhttps://opexatherapeutics.com/OPX-212/OPX-212-Description/default.htmlhttps://opexatherapeutics.com/OPX-212/OPX-212-Description/default_print_1.htmlhttps://opexatherapeutics.com/a.offsetWidth_a.offsetHeight_f_.htmlhttps://opexatherapeutics.com/about-opexa/about-opexa/default.htmlhttps://opexatherapeutics.com/about-opexa/about-opexa/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/board-of-directors/default.htmlhttps://opexatherapeutics.com/about-opexa/board-of-directors/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/contact-us/default.htmlhttps://opexatherapeutics.com/about-opexa/contact-us/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/facility/default.htmlhttps://opexatherapeutics.com/about-opexa/facility/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/management-team.htmlhttps://opexatherapeutics.com/about-opexa/management-team/https://opexatherapeutics.com/about-opexa/management-team/default.htmlhttps://opexatherapeutics.com/about-opexa/management-team/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/scientific-advisory-board/default.htmlhttps://opexatherapeutics.com/about-opexa/scientific-advisory-board/default_print_1.htmlhttps://opexatherapeutics.com/about-opexa/scientific-advisory-board/person-details/default.htmlhttps://opexatherapeutics.com/article_010511_page_release_section_news.htmlhttps://opexatherapeutics.com/bio1.htmlhttps://opexatherapeutics.com/bio2.htmlhttps://opexatherapeutics.com/bio3.htmlhttps://opexatherapeutics.com/board.htmlhttps://opexatherapeutics.com/board.phphttps://opexatherapeutics.com/bottomLeft.htmhttps://opexatherapeutics.com/bottomLeft.htmlhttps://opexatherapeutics.com/cab_ms.htmlhttps://opexatherapeutics.com/cab_ms.phphttps://opexatherapeutics.com/careers.htmlhttps://opexatherapeutics.com/careers.phphttps://opexatherapeutics.com/careers/contact-us/default.htmlhttps://opexatherapeutics.com/careers/contact-us/default_print_1.htmlhttps://opexatherapeutics.com/careers/how-to-apply/default.htmlhttps://opexatherapeutics.com/careers/job-application/default.htmlhttps://opexatherapeutics.com/careers/job-application/default_JobPostingId_59e117be-6b7d-4ddd-bb24-7eb9d958c117.htmlhttps://opexatherapeutics.com/careers/job-details/default.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_08ebd1b5-9997-449a-841e-27851b7aa8aa.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_2d3cec1d-3932-4da0-9014-d1841258e5b7.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_31e05c6a-5b60-4742-be9d-fde328857b0a.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_59e117be-6b7d-4ddd-bb24-7eb9d958c117.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_64e38f65-f0d3-4a2a-a9ba-22492ddbc37d.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_667f139e-bd2e-4680-9553-fc2233d98a8e.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_75049932-0dd5-45a8-8582-668c717982c4.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_a4518cf5-0ea5-45e2-871e-0bc1a828c78f.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_aaa86e37-032e-49ae-ae36-537d8b36971b.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_ce2e63ea-d912-49fe-8a7d-990babfce7a1.htmlhttps://opexatherapeutics.com/careers/job-details/default_JobPostingId_ef527a22-68eb-4678-a889-1f666fa4c5ba.htmlhttps://opexatherapeutics.com/careers/living-in-the-woodlands/default.htmlhttps://opexatherapeutics.com/careers/living-in-the-woodlands/default_print_1.htmlhttps://opexatherapeutics.com/careers/open-positions/default.htmlhttps://opexatherapeutics.com/careers/working-at-opexa/default.htmlhttps://opexatherapeutics.com/clinical-trials/Iimform-clinical-management-tool/default.htmlhttps://opexatherapeutics.com/clinical-trials/Iimform-clinical-management-tool/default_print_1.htmlhttps://opexatherapeutics.com/clinical-trials/abili-t-clinical-study-for-secondary-progressive-multiple-sclerosis-overview.htmlhttps://opexatherapeutics.com/clinical-trials/abili-t-clinical-study-for-secondary-progressive-multiple-sclerosis-overview/https://opexatherapeutics.com/clinical-trials/abili-t-clinical-study-for-secondary-progressive-multiple-sclerosis-overview/default.htmlhttps://opexatherapeutics.com/clinical-trials/abili-t-clinical-study-for-secondary-progressive-multiple-sclerosis-overview/default_print_1.htmlhttps://opexatherapeutics.com/clinical-trials/abili-t-clinical-study-overview/default.htmlhttps://opexatherapeutics.com/contact.htmlhttps://opexatherapeutics.com/contact.phphttps://opexatherapeutics.com/corp.htmlhttps://opexatherapeutics.com/corp.phphttps://opexatherapeutics.com/default_SectionId_89fa79c9-66fa-4638-88ec-596cbca1ab69_LanguageId_1.htmlhttps://opexatherapeutics.com/default_SectionId_a996ffde-c5fb-47ae-89fc-8f5fadabb158_LanguageId_1.htmlhttps://opexatherapeutics.com/diabetes.htmlhttps://opexatherapeutics.com/diabetes.phphttps://opexatherapeutics.com/facility.htmlhttps://opexatherapeutics.com/facility.phphttps://opexatherapeutics.com/files/-for-Rights-Offering_je2ist8kmiy87zpjrxj5v6.htmlhttps://opexatherapeutics.com/files/default_0wwgebxm8ahxyryyaoxp07.htmlhttps://opexatherapeutics.com/files/default_25my3c0pgokq5bga2xqsc8.htmlhttps://opexatherapeutics.com/files/default_2ecfwmt4dq34pjmmx2hsrd.htmlhttps://opexatherapeutics.com/files/default_2gn6kczzvk0458ejsub4st.htmlhttps://opexatherapeutics.com/files/default_2hxdu0psarp26yfp68vuvi.htmlhttps://opexatherapeutics.com/files/default_3ccxvi3kdrars3t3cw30dn.htmlhttps://opexatherapeutics.com/files/default_4amnpe6qndw5z8ekdu8yyy.htmlhttps://opexatherapeutics.com/files/default_4ekmszxfp6ncum6tykccpn.htmlhttps://opexatherapeutics.com/files/default_4i205yidi6dmerc782varr.htmlhttps://opexatherapeutics.com/files/default_50x67oxpa57kda24jtn44j.htmlhttps://opexatherapeutics.com/files/default_5gpfx70k8n0pcqixeid63r.htmlhttps://opexatherapeutics.com/files/default_5tov7ra50zyf4s330wo4nj.htmlhttps://opexatherapeutics.com/files/default_5v2x0u6g76gqbipnkppywq.htmlhttps://opexatherapeutics.com/files/default_5zig32tpvkftzwfjdwvd4d.htmlhttps://opexatherapeutics.com/files/default_70ypbc8z20vzx4imfr3cjo.htmlhttps://opexatherapeutics.com/files/default_7cbj4jxrvw4rn6j5i6nsq4.htmlhttps://opexatherapeutics.com/files/default_7nqn67fdra5zcfvm6c8sny.htmlhttps://opexatherapeutics.com/files/default_7v45g2mqhfrqeppnn6yn55.htmlhttps://opexatherapeutics.com/files/default_8czbhrdx6cdfiz8y04y2qf.htmlhttps://opexatherapeutics.com/files/default_8ppetnjvd27q7ujw5y6k57.htmlhttps://opexatherapeutics.com/files/default_8uquj7622wnrnzot2xi74o.htmlhttps://opexatherapeutics.com/files/default_a4npfvnif0q22x7x34nsb6.htmlhttps://opexatherapeutics.com/files/default_a5uuij44a3xy2t0cq673m6.htmlhttps://opexatherapeutics.com/files/default_aar5jawsyhva2ub8i2nu2a.htmlhttps://opexatherapeutics.com/files/default_axer4jswgsseekifnyo6hb.htmlhttps://opexatherapeutics.com/files/default_b3b5ruaz4mesv43mkeibs4.htmlhttps://opexatherapeutics.com/files/default_bzujabixaapqizn7hz7d05.htmlhttps://opexatherapeutics.com/files/default_cb2mp26qt4h02d0oq67spx.htmlhttps://opexatherapeutics.com/files/default_cs374tgxztx6f32qiriych.htmlhttps://opexatherapeutics.com/files/default_dfi2yo34ke4hvmqqpxrx0h.htmlhttps://opexatherapeutics.com/files/default_domvmsybwppky2y4emvjvf.htmlhttps://opexatherapeutics.com/files/default_dpdd7rpfqeki5pwjno6qem.htmlhttps://opexatherapeutics.com/files/default_dsiiictmrfq38so4t05ptv.htmlhttps://opexatherapeutics.com/files/default_eak5ud5ocon642i2rgai2d.htmlhttps://opexatherapeutics.com/files/default_eoph6tzwatx6newuuetdv8.htmlhttps://opexatherapeutics.com/files/default_es50y4amjkq3nkc05aoxwo.htmlhttps://opexatherapeutics.com/files/default_f6kb2aoknu4s3hy5ievqze.htmlhttps://opexatherapeutics.com/files/default_f73rqacq7v3b4kond8hxub.htmlhttps://opexatherapeutics.com/files/default_fbvmwc8oqbytoxpkv5y46z.htmlhttps://opexatherapeutics.com/files/default_fksd47qstw4spkxa27b5ze.htmlhttps://opexatherapeutics.com/files/default_fsqsexjdq4fvgmuirhknkx.htmlhttps://opexatherapeutics.com/files/default_ghrdr8ferxdtegtcy8h677.htmlhttps://opexatherapeutics.com/files/default_gkesbm8uve2yhy5hzqrnw5.htmlhttps://opexatherapeutics.com/files/default_gz2jxxa8dvy4b8cruw77ux.htmlhttps://opexatherapeutics.com/files/default_hc6ytce6cy8h5h5xcipeyb.htmlhttps://opexatherapeutics.com/files/default_hpx27zirhi35pfwoczfjaz.htmlhttps://opexatherapeutics.com/files/default_hsrwrium53yu2a8txqxcnu.htmlhttps://opexatherapeutics.com/files/default_i3xh88m4ej5ta67bcyp06e.htmlhttps://opexatherapeutics.com/files/default_idh63uhg4gyzd5mmkfaz02.htmlhttps://opexatherapeutics.com/files/default_ighpsefnf7a5cjox6pxwxa.htmlhttps://opexatherapeutics.com/files/default_isti87ss3dzz4wfm0g4gh8.htmlhttps://opexatherapeutics.com/files/default_iwx8ucknvby5dmt3b07vi7.htmlhttps://opexatherapeutics.com/files/default_j5hr5q3dkchbt3bbqn4206.htmlhttps://opexatherapeutics.com/files/default_j5k56p0bx220fe47sdv3fb.htmlhttps://opexatherapeutics.com/files/default_jc2qf54gc0avausr868rej.htmlhttps://opexatherapeutics.com/files/default_jmbqm0hyas7tc6w2o5504g.htmlhttps://opexatherapeutics.com/files/default_k73byu45r7oh7463zyjezh.htmlhttps://opexatherapeutics.com/files/default_kgsw6wyrbnwj7gq8r55tbz.htmlhttps://opexatherapeutics.com/files/default_kv8cjyxe64sviksi85gy6j.htmlhttps://opexatherapeutics.com/files/default_kx30zz0sawg8fog32jvevs.htmlhttps://opexatherapeutics.com/files/default_m4ujbwv0x5h30on7qhk5hk.htmlhttps://opexatherapeutics.com/files/default_n2ptnmnajajb7k34riaz34.htmlhttps://opexatherapeutics.com/files/default_nqgd2pthopvidtvn84jcn6.htmlhttps://opexatherapeutics.com/files/default_o064drhy2jmqztbrurhdvi.htmlhttps://opexatherapeutics.com/files/default_odpx6vyjfeux3k5k6xda7n.htmlhttps://opexatherapeutics.com/files/default_opf2gumsd7cwfuwii63067.htmlhttps://opexatherapeutics.com/files/default_pjkfnftus6hvhz3kwp5n4b.htmlhttps://opexatherapeutics.com/files/default_pqvwvkfn0qmdmgk0hvfsu0.htmlhttps://opexatherapeutics.com/files/default_print_1_0rr74tcfi7dhbp02jqdg7f.htmlhttps://opexatherapeutics.com/files/default_print_1_hneqjgkwxxvycpfceqbhb2.htmlhttps://opexatherapeutics.com/files/default_py3mh3agnwg3sk3hckqsjx.htmlhttps://opexatherapeutics.com/files/default_qf0yr64wemcsygtkv5253m.htmlhttps://opexatherapeutics.com/files/default_qt5k6yvgcjdnwp6d7ne4k3.htmlhttps://opexatherapeutics.com/files/default_r25zx6ezdh86aaot8c5dbp.htmlhttps://opexatherapeutics.com/files/default_sjco0r6oxcgbjjovhkpzvd.htmlhttps://opexatherapeutics.com/files/default_sycfjb6q3tzwh8xbi8miee.htmlhttps://opexatherapeutics.com/files/default_t2hfa2v7bc8g7wuygjmbm7.htmlhttps://opexatherapeutics.com/files/default_te2j4o36j66t324fd8psb6.htmlhttps://opexatherapeutics.com/files/default_th0qmck8ciccmc8n8uyi0w.htmlhttps://opexatherapeutics.com/files/default_tk85yg8un82toe5mazqcfp.htmlhttps://opexatherapeutics.com/files/default_u5omhzvv4dnskjt6pno6ym.htmlhttps://opexatherapeutics.com/files/default_uo522gv3gohescteuouuy8.htmlhttps://opexatherapeutics.com/files/default_uq3r5vf8y0kz3nrkw3wca5.htmlhttps://opexatherapeutics.com/files/default_w4vb68coniw306ymwpbz33.htmlhttps://opexatherapeutics.com/files/default_wp3vc3gwb7itbtxh2ekezt.htmlhttps://opexatherapeutics.com/files/default_xcpcm2hnnghikf7iwor35z.htmlhttps://opexatherapeutics.com/files/default_xtn8jrx70ej3s7beeprm6u.htmlhttps://opexatherapeutics.com/files/default_xzyhuke3hauivqjrdjpm74.htmlhttps://opexatherapeutics.com/files/default_yveik4gpb7ykfq4em7ws8q.htmlhttps://opexatherapeutics.com/files/default_yxt3m824yxap54g6vevauj.htmlhttps://opexatherapeutics.com/files/default_z456gfckn0gke5hgcyahha.htmlhttps://opexatherapeutics.com/files/default_zurdf7fwzmxcs3xamr8oh7.htmlhttps://opexatherapeutics.com/files/default_zvr03xoqqqziuqhf5odr80.htmlhttps://opexatherapeutics.com/files/default_zzaihhn47z2gxx7ccm73pg.htmlhttps://opexatherapeutics.com/files/n-of-Rights-Offering_s6kmkia5ez4x68k5icqyee.htmlhttps://opexatherapeutics.com/files/r-Multiple-Sclerosis_8ms2idnfk4euqi4qn7mnaz.htmlhttps://opexatherapeutics.com/index01be_page_release_section_news_article_041912.htmlhttps://opexatherapeutics.com/index050a_page_investor-faq_section_investors.htmlhttps://opexatherapeutics.com/index088f_page_terms-of-use_section_home.htmlhttps://opexatherapeutics.com/index09ec_page_analyst-coverage_section_investors.htmlhttps://opexatherapeutics.com/index0c95_page_management_section_about.htmlhttps://opexatherapeutics.com/index0cf2.htmlhttps://opexatherapeutics.com/index0cf2_page_release_section_news_article_111412.htmlhttps://opexatherapeutics.com/index0d4b_page_overview_section_tovaxin.htmlhttps://opexatherapeutics.com/index108c_page_contact_section_investors.htmlhttps://opexatherapeutics.com/index13d5_page_stock_section_investors.htmlhttps://opexatherapeutics.com/index13press.htmlhttps://opexatherapeutics.com/index13press_page_releases_section_news.htmlhttps://opexatherapeutics.com/index1f87_page_release_section_news_article_091712.htmlhttps://opexatherapeutics.com/index257c_page_stem-cell-platform_section_technology.htmlhttps://opexatherapeutics.com/index3197_page_annual-reports_section_investors.htmlhttps://opexatherapeutics.com/index375b_page_release_section_news_article_051112.htmlhttps://opexatherapeutics.com/index3cc6_page_release_section_news_article_111212.htmlhttps://opexatherapeutics.com/index407e_page_sec_section_investors.htmlhttps://opexatherapeutics.com/index44ac.htmlhttps://opexatherapeutics.com/index44ac_page_advisory-board_section_home.htmlhttps://opexatherapeutics.com/index4614.htmlhttps://opexatherapeutics.com/index4614_page_positions_section_careers.htmlhttps://opexatherapeutics.com/index4ab0_page_board-of-directors_section_home.htmlhttps://opexatherapeutics.com/index4f40_page_advisory-board_section_about.htmlhttps://opexatherapeutics.com/index5398.htmlhttps://opexatherapeutics.com/index5398_page_management_section_home.htmlhttps://opexatherapeutics.com/index53b9.htmlhttps://opexatherapeutics.com/index53b9_page_contact_section_about.htmlhttps://opexatherapeutics.com/index54e3_page_2007_section_news.htmlhttps://opexatherapeutics.com/index56d6_page_2006_section_news.htmlhttps://opexatherapeutics.com/index58d8_page_release_section_news_article_081312.htmlhttps://opexatherapeutics.com/index599b_page_sitemap_section_home.htmlhttps://opexatherapeutics.com/index5dd5_page_privacy-policy_section_home.htmlhttps://opexatherapeutics.com/index644a_page_release_section_news_article_022912.htmlhttps://opexatherapeutics.com/index691f.htmlhttps://opexatherapeutics.com/index691f_page_releases_section_news.htmlhttps://opexatherapeutics.com/index6ee6.htmlhttps://opexatherapeutics.com/index6ee6_page_t-cell-platform_section_technology.htmlhttps://opexatherapeutics.com/index743d.htmlhttps://opexatherapeutics.com/index743d_page_contact_section_careers.htmlhttps://opexatherapeutics.com/index748f_page_2011_section_news.htmlhttps://opexatherapeutics.com/index7656_page_clinical-studies_section_tovaxin.htmlhttps://opexatherapeutics.com/index7713_page_release_section_news_article_011712.htmlhttps://opexatherapeutics.com/index7926_page_corporate-governance_section_investors.htmlhttps://opexatherapeutics.com/index7cb7_page_release_section_news_article_072612.htmlhttps://opexatherapeutics.com/index7d13_page_facility_section_about.htmlhttps://opexatherapeutics.com/index7e69_page_overview_section_patients.htmlhttps://opexatherapeutics.com/index7f17_page_board-of-directors_section_about.htmlhttps://opexatherapeutics.com/index852c_page_manufacturing_section_technology.htmlhttps://opexatherapeutics.com/index8720.htmlhttps://opexatherapeutics.com/index8720_page_tovaxin_section_tovaxin.htmlhttps://opexatherapeutics.com/index8922.htmlhttps://opexatherapeutics.com/index8922_page_stock_section_home.htmlhttps://opexatherapeutics.com/index8a62_page_release_section_news_article_022712.htmlhttps://opexatherapeutics.com/index93ae.htmlhttps://opexatherapeutics.com/index93ae_page_home_section_home.htmlhttps://opexatherapeutics.com/index9622_page_alerts_section_investors.htmlhttps://opexatherapeutics.com/index9823_page_calendar_section_news.htmlhttps://opexatherapeutics.com/index_php.htmlhttps://opexatherapeutics.com/indexa2a5_page_webcasts_section_news.htmlhttps://opexatherapeutics.com/indexa6a7_page_release_section_news_article_111312.htmlhttps://opexatherapeutics.com/indexa88d_page_2009_section_news.htmlhttps://opexatherapeutics.com/indexaa2a.htmlhttps://opexatherapeutics.com/indexaa2a.html?page=overview&section=investorshttps://opexatherapeutics.com/indexaa40_page_abilit_section_abilit.htmlhttps://opexatherapeutics.com/indexaf65_page_release_section_news_article_020812.htmlhttps://opexatherapeutics.com/indexb1e9_page_casts_section_investors.htmlhttps://opexatherapeutics.com/indexb30c_page_publications_section_news.htmlhttps://opexatherapeutics.com/indexb548_page_2005_section_news.htmlhttps://opexatherapeutics.com/indexb74d_page_release_section_news_article_091212.htmlhttps://opexatherapeutics.com/indexc4cf.htmlhttps://opexatherapeutics.com/indexc4cf_page_working-at-opexa_section_careers.htmlhttps://opexatherapeutics.com/indexc4de_page_news_section_investors.htmlhttps://opexatherapeutics.com/indexcb7e.htmlhttps://opexatherapeutics.com/indexcb7e_page_contact_section_home.htmlhttps://opexatherapeutics.com/indexcbaf_page_presentations_section_news.htmlhttps://opexatherapeutics.com/indexceb5_page_videoQA_section_about.htmlhttps://opexatherapeutics.com/indexd7db_page_information_section_investors.htmlhttps://opexatherapeutics.com/indexdb99_page_2008_section_news.htmlhttps://opexatherapeutics.com/indexdc0e.htmlhttps://opexatherapeutics.com/indexdc0e_page_apply_section_careers.htmlhttps://opexatherapeutics.com/indexdd0c_page_release_section_news_article_091012.htmlhttps://opexatherapeutics.com/indexe069_page_woodlands_section_careers.htmlhttps://opexatherapeutics.com/indexe25b.htmlhttps://opexatherapeutics.com/indexe25b_page_tovaxin_section_home.htmlhttps://opexatherapeutics.com/indexea24.htmlhttps://opexatherapeutics.com/indexea24_page_about_section_about.htmlhttps://opexatherapeutics.com/indexebb7_page_2010_section_news.htmlhttps://opexatherapeutics.com/indexef69_page_publications_section_tovaxin.htmlhttps://opexatherapeutics.com/indexf1e8_page_tovaxin_section_partnership.htmlhttps://opexatherapeutics.com/indexf287_page_terms_section_tovaxin.htmlhttps://opexatherapeutics.com/indexf675_page_release_section_news_article_052112.htmlhttps://opexatherapeutics.com/indexfba0_page_release_section_news_article_110512.htmlhttps://opexatherapeutics.com/info.htmlhttps://opexatherapeutics.com/info.phphttps://opexatherapeutics.com/investor/invInclude.htmhttps://opexatherapeutics.com/investor/invInclude.htmlhttps://opexatherapeutics.com/investors-relations/analyst-coverage/default.htmlhttps://opexatherapeutics.com/investors-relations/contact-us/default.htmlhttps://opexatherapeutics.com/investors-relations/contact-us/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/corporate-governance/bboard-of-directors/default.htmlhttps://opexatherapeutics.com/investors-relations/corporate-governance/default.htmlhttps://opexatherapeutics.com/investors-relations/corporate-governance/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/corporate-governance/management-team/default.htmlhttps://opexatherapeutics.com/investors-relations/email-alerts/Email-Alert-Activation/default.htmlhttps://opexatherapeutics.com/investors-relations/email-alerts/Email-Alert-Unsubscribe/default.htmlhttps://opexatherapeutics.com/investors-relations/email-alerts/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/https://opexatherapeutics.com/investors-relations/events-and-presentations/2010/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2011/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2012/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2013/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2014/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2015/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/2016/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2013/Aegis-Capital-Corp-2013-Healthcare-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2013/CEO-New-York-Conference/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2013/Opexa-Therapeutics-First-Quarter-Earnings-and-Corporate-Update/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2013/The-9th-Annual-Burrill-Personalized-Medicine-Meeting/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2014/Opexa-Therapeutics-Investor-Update/default.htmlhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2015/Opexa-First-Quarter-Earnings-and-Corporate-Update5122015/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2015/Opexa-Therapeutics-Analyst-and-Investor-Event/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2015/Rodman--Renshaw-17th-Annual-Healthcare-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2016/18th-Annual-BIO-CEO--Investor-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2016/Opexa-2015-Year-End-Earnings-and-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2016/Opexa-First-Quarter-Earnings-and-Corporate-Update-2016/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2016/Opexa-Second-2016-Quarter-Earnings-and-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/events-and-presentations/event-details/2016/Rodman--Renshaw-18th-Annual-Healthcare-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/financial-reports/default.htmlhttps://opexatherapeutics.com/investors-relations/financial-reports/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/investor-faqs/default.htmlhttps://opexatherapeutics.com/investors-relations/investor-faqs/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2005/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2006/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2007/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2008/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2009/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2010/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2011/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2012/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2013/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2014/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2015/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2016/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/2017/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2009/Opexas-Stem-Cell-Therapy-for-Diabetes-Shows-Progress/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2012/Opexa-Initiates-Late-Stage-Clinical-Study-of-Tcelna-in-Patients-with-Secondary-Progressive-Multiple-Sclerosis-SPMS/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2012/Opexa-Receives-Clinical-Trial-Approval-from-Health-Canada-for-Novel-T-Cell-Therapy/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/In-Honor-of-World-MS-Day-Opexa-Therapeutics-to-Ring-The-NASDAQ-Stock-Market-Closing-Bell-on-May-28/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Merck-Serono-and-Opexa-Therapeutics-Enter-into-Option-and-License-Agreement-for-Development-of-Tcelna-imilecleucel-T-for-Treatment-of-Multiple-Sclerosis/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Announces-Changes-to-Senior-Management-Team/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-First-Quarter-2013-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Closes-Private-Note-Offering/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-UnderwritersOptionto-Purchase-Additional-Shares/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Inc-Announces-Pricing-of-Common-Stock-and-Warrant-Offering/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Recognizes-World-MS-Day-and-Will-Present-Poster-With-Secondary-Progressive-Multiple-Sclerosis-Data-at-CMSC--ACTRIMS-Annual-Meeting/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Listing-Requirement/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Reports-First-Quarter-2013-Financial-Results-and-Provides-Corporate-Update/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-Reports-Year-End-2012-Financial-Results-and-Provides-Corporate-Update/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-to-Present-at-the-15th-Annual-BIO-CEO--Investor-Conference/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-to-Present-at-the-6th-Annual-European-Life-Science-CEO-Forum/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-Therapeutics-to-Present-at-the-Regenerative-Medicine---A-Fundamental-Shift-in-Science--Culture-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/Opexa-to-Present-at-the-Aegis-Capital-Corp-2013-Healthcare-Conference/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2013/opexa-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwritersoptionto-purchase-additional-shares/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/On-World-MS-Day-Its-Time-to-Recognize-Our-Differences/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Reaches-Enrollment-Target-in-Phase-IIb-Trial-of-Personalized-Immunotherapy-for-Secondary-Progressive-Multiple-Sclerosis/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Strengthens-Patent-Portfolio-with-Expansion-Into-B-cell-Diseases-and-Announces-Allowance-of-98th-T-cell-Patent/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Announces-Analyst-and-Investor-Event/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Second-Quarter-2014-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Year-End-2013-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-to-Discuss-First-Quarter-2014-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Appoints-Prof-Hans-Peter-Hartung-and-Timothy-Barabe-to-the-Board-of-Directors/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-CEO-Invited-to-Join-Personalized-Medicine-Panel-at-New-York-CEO-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-CEO-Letter-to-Shareholders/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-CEO-to-Present-at-the-2014-Leerink-Global-Healthcare-Conference/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Chief-Scientific-Officer-Invited-as-Guest-Speaker-at-the-Phacilitate-Cell--Gene-Therapy-Forum/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Inc-Announces-Proposed-Public-Offering-of-Common-Stock/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Inc-Announces-Termination-of-Public-Offering-of-Common-Stock/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Joins-Russell-Microcap-Index/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Reports-First-Quarter-2014-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Reports-Second-Quarter-2014-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Reports-Year-End-2013-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Selected-as-One-of-the-Top-10-Advanced-Therapy-Projects-to-Watch/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-Supports-National-Multiple-Sclerosis-Society-and-Walk-MS/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-to-Attend-the-American-Academy-of-Neurology-Annual-Meeting/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-to-Present-at-Cleveland-Clinics-12th-Annual-Medical-Innovation-Summit/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-to-Present-at-September-Conferences/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-to-Present-at-the-16th-Annual-BIO-CEO--Investor-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2014/Opexa-Therapeutics-to-Target-Rare-Disease-Neuromyelitis-Optica-NMO-as-next-Development-Program/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Amends-Agreement-with-Merck-Serono-and-Receives-Additional-3-Million-Payment-to-Support-Ongoing-Development-of-Tcelna-for-Multiple-Sclerosis/https://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Amends-Agreement-with-Merck-Serono-and-Receives-Additional-3-Million-Payment-to-Support-Ongoing-Development-of-Tcelna-for-Multiple-Sclerosis/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Announces-Granting-of-New-T-cell-Patents-Covering-Tcelna-Patent-Estate-Increases-to-160-Issued-Patents/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Announces-Reverse-Stock-Split/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Hires-Experienced-Pharmaceutical-Executive-as-Vice-President-of-Business-Development/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Secures-Private-Funding-for-its-NMO-Orphan-Development-Program-Including-Planned-Phase-III-Clinical-Study/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Announces-News-Release-Schedule-for-Third-Quarter-2015-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-First-Quarter-2015-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Second-Quarter-2015-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Announces-Supportive-Preclinical-Study-Results-for-its-Neuromyelitis-Optica-NMO-Program/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-CEO-Invited-to-Participate-in-Multiple-May-Conferences/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-CEO-to-Present-at-BIO-2015-International-Convention/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Chosen-as-One-of-the-Top-Autoimmune-Therapy-Projects-to-Watch/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Inc-Announces-Completion-of-Rights-Offering/https://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Inc-Announces-Completion-of-Rights-Offering/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Inc-Announces-Record-Date-and-Subscription-Price-for-Rights-Offering/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Inc-Files-Registration-Statement-for-Rights-Offering/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Invited-to-Present-Biomarker-Data-from-NMO-Patients-at-The-American-Academy-of-Neurology-AAN-2015-Annual-Meeting/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Listing-Requirement/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reminds-Shareholders-That-Rights-Offering-Expires-on-April-8-2015-at-500-PM-ET/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reminds-Shareholders-That-Rights-Offering-Ownership-Date-and-Time-is-Tuesday-March-10-2015-at-400-PM-ET/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reports-First-Quarter-2015-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reports-Second-Quarter-2015-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reports-Third-Quarter-2015-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-Reports-Year-End-2014-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-to-Host-Analyst-and-Investor-Event-on-November-10-in-New-York/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-to-Present-at-BIO-Investor-Forum/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-to-Present-at-September-Conferences/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2015/Opexa-Therapeutics-to-Present-at-the-2015-Marcum-Microcap-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Announces-Reduction-in-Workforce-in-Light-of-Top-Line-Results-from-Phase-2b-Abili-T-Trial-of-TcelnaR-imilecleucel-T-in-Secondary-Progressive-Multiple-Sclerosis/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Launches-Restructuring-Initiative-to-Focus-Use-of-Resources-Ahead-of-Key-Phase-2-Data-Expected-in-Early-Q4-2016/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-First-Quarter-2016-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Second-Quarter-2016-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Year-End-2015-Financial-Results/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Announces-Phase-2b-Abili-T-Trial-of-Tcelna-imilecleucel-T-in-Secondary-Progressive-Multiple-Sclerosis-Did-Not-Meet-Primary-Endpoint/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Reports-2015-Year-End-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Reports-First-Quarter-2016-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Reports-Second-Quarter-2016-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-Reports-Third-Quarter-2016-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-to-Present-at-Rodman--Renshaw-18th-Annual-Global-Investment-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-Therapeutics-to-Present-at-the-18th-Annual-BIO-CEO-and-Investor-Conference/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2016/Opexa-to-Attend-the-Third-International-Conference-on-the-Progress-of-Regenerative-Medicine-and-Its-Cultural-Impact/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2017/Acer-Therapeutics-and-Opexa-Therapeutics-Sign-Merger-Agreement/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2017/Acer-Therapeutics-and-Opexa-Therapeutics-Sign-Merger-Agreement/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2017/Opexa-Facility-Becomes-Foundation-for-Contract-Manufacturing-and-Development-Organization-for-Cellular-Therapies/default.aspxhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2017/Opexa-Therapeutics-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update/default.htmlhttps://opexatherapeutics.com/investors-relations/press-releases/press-release-details/2017/Opexa-Therapeutics-Sets-Date-for-Special-Meeting-of-Shareholders/default.aspxhttps://opexatherapeutics.com/investors-relations/sec-filings.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/https://opexatherapeutics.com/investors-relations/sec-filings/1999/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2000/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2001/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2002/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2003/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2004/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2005/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2006/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2007/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2008/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2009/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2010/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2011/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2012/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2013/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2014/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2015/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/2016/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11089536.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11089549.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11089565.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11152605.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11231318.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11258954.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11258975.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11267959.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11280909.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11280919.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11281252.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11311090.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11381907.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11397166.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398014.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398018.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398020.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398021.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398025.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398026.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11398183.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11406413.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11470791.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11470800.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11470805.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11470807.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11540129.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11540144.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11540970.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11588613.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11619703.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11619704.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11619705.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11619706.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11653108.htmlhttps://opexatherapeutics.com/investors-relations/sec-filings/sec-filings-details/default_FilingId_11661373.htmlhttps://opexatherapeutics.com/investors-relations/stock-information/default.htmlhttps://opexatherapeutics.com/investors-relations/stock-information/default_print_1.htmlhttps://opexatherapeutics.com/investors-relations/why-invest.htmlhttps://opexatherapeutics.com/investors-relations/why-invest/https://opexatherapeutics.com/investors-relations/why-invest/default.htmlhttps://opexatherapeutics.com/investors-relations/why-invest/default_print_1.htmlhttps://opexatherapeutics.com/manag.htmlhttps://opexatherapeutics.com/manag.phphttps://opexatherapeutics.com/monocyteQuick.htmhttps://opexatherapeutics.com/monocyteQuick.htmlhttps://opexatherapeutics.com/monocyteWMV.htmhttps://opexatherapeutics.com/monocyteWMV.htmlhttps://opexatherapeutics.com/ms.htmlhttps://opexatherapeutics.com/ms.phphttps://opexatherapeutics.com/msQuick.htmhttps://opexatherapeutics.com/msQuick.htmlhttps://opexatherapeutics.com/msWMV.htmhttps://opexatherapeutics.com/msWMV.htmlhttps://opexatherapeutics.com/msinfo.htmhttps://opexatherapeutics.com/msinfo.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2005/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2006/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2007/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2008/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2009/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2010/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2011/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2012/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2013/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2015/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/2016/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/default.htmlhttps://opexatherapeutics.com/news-and-resources/conference-and-meeting-presentations/default_print_1.htmlhttps://opexatherapeutics.com/news-and-resources/multimedia/default.htmlhttps://opexatherapeutics.com/news-and-resources/multimedia/default_print_1.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2005/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2006/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2007/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2008/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2009/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2010/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2011/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2012/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2013/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2014/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2015/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/2016/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/default_print_1.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2007/Opexa-Therapeutics-to-Present-Progress-on-Development-of-Monocyte-Derived-Pancreatic-Islet-Cells-for-Diabetes/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Merck-Serono-and-Opexa-Therapeutics-Enter-into-Option-and-License-Agreement-for-Development-of-Tcelna-imilecleucel-T-for-Treatment-of-Multiple-Sclerosis/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Opexa-Therapeutics-CEO-to-Appear-on-The-RedChip-Money-Report-on-Fox-Business-News/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Opexa-Therapeutics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-UnderwritersOptionto-Purchase-Additional-Shares/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Opexa-Therapeutics-Inc-Announces-Pricing-of-Common-Stock-and-Warrant-Offering/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Opexa-Therapeutics-Provides-MS-Trial-Enrollment-Update-70-of-Patients-Enrolled/default.htmlhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Strengthens-Patent-Portfolio-with-Expansion-Into-B-cell-Diseases-and-Announces-Allowance-of-98th-T-cell-Patent/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Therapeutics-Announces-Analyst-and-Investor-Event/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Therapeutics-CEO-Invited-to-Join-Personalized-Medicine-Panel-at-New-York-CEO-Conference/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Therapeutics-Reports-Third-Quarter-2014-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/Opexa-Therapeutics-to-Present-at-September-Conferences/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2014/opexa-therapeutics-reports-third-quarter-2014-financial-results-and-provides-corporate-update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Secures-Private-Funding-for-its-NMO-Orphan-Development-Program-Including-Planned-Phase-III-Clinical-Study/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Announces-Supportive-Preclinical-Study-Results-for-its-Neuromyelitis-Optica-NMO-Program/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Inc-Announces-Record-Date-and-Subscription-Price-for-Rights-Offering/https://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Inc-Announces-Record-Date-and-Subscription-Price-for-Rights-Offering/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Inc-Files-Registration-Statement-for-Rights-Offering/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Invited-to-Present-Biomarker-Data-from-NMO-Patients-at-The-American-Academy-of-Neurology-AAN-2015-Annual-Meeting/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Reminds-Shareholders-That-Rights-Offering-Expires-on-April-8-2015-at-500-PM-ET/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-Reports-First-Quarter-2015-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2015/Opexa-Therapeutics-to-Present-at-September-Conferences/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Launches-Restructuring-Initiative-to-Focus-Use-of-Resources-Ahead-of-Key-Phase-2-Data-Expected-in-Early-Q4-2016/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-First-Quarter-2016-Financial-Results/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Announces-News-Release-and-Conference-Call-Schedule-to-Discuss-Year-End-2015-Financial-Results/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Announces-Phase-2b-Abili-T-Trial-of-Tcelna-imilecleucel-T-in-Secondary-Progressive-Multiple-Sclerosis-Did-Not-Meet-Primary-Endpoint/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Reports-2015-Year-End-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Reports-First-Quarter-2016-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-Reports-Second-Quarter-2016-Financial-Results-and-Provides-Corporate-Update/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-Therapeutics-to-Present-at-the-18th-Annual-BIO-CEO-and-Investor-Conference/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2016/Opexa-to-Attend-the-Third-International-Conference-on-the-Progress-of-Regenerative-Medicine-and-Its-Cultural-Impact/default.aspxhttps://opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2017/Opexa-Therapeutics-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update/default.htmlhttps://opexatherapeutics.com/news-and-resources/publications/default.htmlhttps://opexatherapeutics.com/news-and-resources/publications/default_print_1.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2009/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2010/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2011/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2012/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2013/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2014/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2015/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/2016/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/default.htmlhttps://opexatherapeutics.com/news-and-resources/webcasts/default_print_1.htmlhttps://opexatherapeutics.com/opx-212/opx-212-description/default.htmlhttps://opexatherapeutics.com/page_abilit_section_abilit.htmlhttps://opexatherapeutics.com/page_about_section_about.htmlhttps://opexatherapeutics.com/page_advisory-board_section_home.htmlhttps://opexatherapeutics.com/page_board-of-directors_section_home.htmlhttps://opexatherapeutics.com/page_calendar_section_news.htmlhttps://opexatherapeutics.com/page_contact_section_about.htmlhttps://opexatherapeutics.com/page_contact_section_home.htmlhttps://opexatherapeutics.com/page_home_section_home.htmlhttps://opexatherapeutics.com/page_management_section_about.htmlhttps://opexatherapeutics.com/page_management_section_home.htmlhttps://opexatherapeutics.com/page_overview_section_investors.htmlhttps://opexatherapeutics.com/page_overview_section_patients.htmlhttps://opexatherapeutics.com/page_positions_section_careers.htmlhttps://opexatherapeutics.com/page_privacy-policy_section_home.htmlhttps://opexatherapeutics.com/page_release_section_news_article_010511.htmlhttps://opexatherapeutics.com/page_release_section_news_article_011712.htmlhttps://opexatherapeutics.com/page_release_section_news_article_022712.htmlhttps://opexatherapeutics.com/page_release_section_news_article_022912.htmlhttps://opexatherapeutics.com/page_release_section_news_article_022912_elq_2de28650195a4946a27e431b5e6869e5.htmlhttps://opexatherapeutics.com/page_release_section_news_article_041410.htmlhttps://opexatherapeutics.com/page_release_section_news_article_041912.htmlhttps://opexatherapeutics.com/page_release_section_news_article_042710.htmlhttps://opexatherapeutics.com/page_release_section_news_article_051112.htmlhttps://opexatherapeutics.com/page_release_section_news_article_052112.htmlhttps://opexatherapeutics.com/page_release_section_news_article_062811.htmlhttps://opexatherapeutics.com/page_release_section_news_article_072612.htmlhttps://opexatherapeutics.com/page_release_section_news_article_081312.htmlhttps://opexatherapeutics.com/page_release_section_news_article_091012.htmlhttps://opexatherapeutics.com/page_release_section_news_article_091211.htmlhttps://opexatherapeutics.com/page_release_section_news_article_091212.htmlhttps://opexatherapeutics.com/page_release_section_news_article_091712.htmlhttps://opexatherapeutics.com/page_release_section_news_article_091911.htmlhttps://opexatherapeutics.com/page_release_section_news_article_110411.htmlhttps://opexatherapeutics.com/page_release_section_news_article_110811.htmlhttps://opexatherapeutics.com/page_release_section_news_article_120911.htmlhttps://opexatherapeutics.com/page_releases_section_news.htmlhttps://opexatherapeutics.com/page_sec_section_investors.htmlhttps://opexatherapeutics.com/page_sitemap_section_home.htmlhttps://opexatherapeutics.com/page_stock_section_home.htmlhttps://opexatherapeutics.com/page_t-cell-platform_section_technology.htmlhttps://opexatherapeutics.com/page_terms-of-use_section_home.htmlhttps://opexatherapeutics.com/page_tovaxin.htmlhttps://opexatherapeutics.com/page_tovaxin_section_home.htmlhttps://opexatherapeutics.com/page_tovaxin_section_partnership.htmlhttps://opexatherapeutics.com/page_tovaxin_section_tovaxin.htmlhttps://opexatherapeutics.com/page_videoQA_section_about.htmlhttps://opexatherapeutics.com/page_webcasts_section_news.htmlhttps://opexatherapeutics.com/page_working-at-opexa_section_careers.htmlhttps://opexatherapeutics.com/patents.htmlhttps://opexatherapeutics.com/patents.phphttps://opexatherapeutics.com/pipeline.htmlhttps://opexatherapeutics.com/pipeline.phphttps://opexatherapeutics.com/pressaccess.htmlhttps://opexatherapeutics.com/pressaccess.phphttps://opexatherapeutics.com/print_1_wordpress.htmlhttps://opexatherapeutics.com/privacy-policy/default.htmlhttps://opexatherapeutics.com/privacy-policy/default_print_1.htmlhttps://opexatherapeutics.com/q1.htmlhttps://opexatherapeutics.com/q2.htmlhttps://opexatherapeutics.com/q3.htmlhttps://opexatherapeutics.com/q4.htmlhttps://opexatherapeutics.com/q5.htmlhttps://opexatherapeutics.com/q6.htmlhttps://opexatherapeutics.com/q7.htmlhttps://opexatherapeutics.com/q8.htmlhttps://opexatherapeutics.com/q9.htmlhttps://opexatherapeutics.com/related.htmlhttps://opexatherapeutics.com/related.phphttps://opexatherapeutics.com/researchReports.htmlhttps://opexatherapeutics.com/researchReports.phphttps://opexatherapeutics.com/scientific.htmlhttps://opexatherapeutics.com/scientific.phphttps://opexatherapeutics.com/slideshow/embed_code/key/xqO8Ni1R6wHUMM_ext_iframe.htmlhttps://opexatherapeutics.com/tcellQuick.htmhttps://opexatherapeutics.com/tcellQuick.htmlhttps://opexatherapeutics.com/tcellWMV.htmhttps://opexatherapeutics.com/tcellWMV.htmlhttps://opexatherapeutics.com/tcelna/Publications/default.htmlhttps://opexatherapeutics.com/tcelna/Publications/default_print_1.htmlhttps://opexatherapeutics.com/tcelna/ms-overview.htmlhttps://opexatherapeutics.com/tcelna/ms-overview/https://opexatherapeutics.com/tcelna/ms-overview/default.htmlhttps://opexatherapeutics.com/tcelna/ms-overview/default_print_1.htmlhttps://opexatherapeutics.com/tcelna/tcelna-description/default.htmlhttps://opexatherapeutics.com/tcelna/tcelna-description/default_print_1.htmlhttps://opexatherapeutics.com/tcelna/terms-phase-2b-overview.htmlhttps://opexatherapeutics.com/tcelna/terms-phase-2b-overview/https://opexatherapeutics.com/tcelna/terms-phase-2b-overview/default.htmlhttps://opexatherapeutics.com/tcelna/terms-phase-2b-overview/default_print_1.htmlhttps://opexatherapeutics.com/technology/Pipeline/default.htmlhttps://opexatherapeutics.com/technology/Pipeline/default_print_1.htmlhttps://opexatherapeutics.com/technology/default.htmlhttps://opexatherapeutics.com/technology/default_print_1.htmlhttps://opexatherapeutics.com/technology/opexa-cgmp-manufacturing/default.htmlhttps://opexatherapeutics.com/technology/opexa-cgmp-manufacturing/default_print_1.htmlhttps://opexatherapeutics.com/technology/stem-cell-platform/default.htmlhttps://opexatherapeutics.com/technology/t-cell-platform/default.htmlhttps://opexatherapeutics.com/technology/t-cell-platform/default_print_1.htmlhttps://opexatherapeutics.com/terms-of-use/default.htmlhttps://opexatherapeutics.com/terms-of-use/default_print_1.htmlhttps://opexatherapeutics.com/tovaxin.htmlhttps://opexatherapeutics.com/tovaxin.phphttps://opexatherapeutics.com/tovaxintrials.htmlhttps://opexatherapeutics.com/tovaxintrials.phphttps://opexatherapeutics.com/video234a_KeepThis_true_TB_iframe_true_height_290_width_320.htmlhttps://opexatherapeutics.com/videoQA.htmlhttps://opexatherapeutics.com/video_KeepThis_true_TB_iframe_true_height_290_width_320.htmlhttps://opexatherapeutics.com/videos/videocd48_KeepThis_true_TB_iframe_true_height_270_width_320.htmlhttps://opexatherapeutics.com/webcasts.htmlhttps://opexatherapeutics.com/webcasts.php